Neurol. praxi. 2020;21(2):120-124 | DOI: 10.36290/neu.2020.059

The new trends in multiple sclerosis treatment

prof. MUDr. Ľubomír Lisý, DrSc.
Neurologická klinika LF SZU a UNB, Nemocnica Ružinov, Bratislava

During several last years, important progress in medicamentous treatment of multiple sclerosis has been achieved. Every year new molecules with higher degree of efficiency are approved. Medication with continuous application is replaced by pulse therapy that improves adherence of patients to the therapy. Used medication beside anti-inflammatory effect has also immunosuppressive effect. The treated patients are under increased risk of infectious complications. Identification of heterogenous pathomechanisms of the disease in the future could help to find better approach to the treatment of inflammation and accompanying neurodegeneration.

Keywords: multiple sclerosis, immunotherapy, monoclonal antibodies.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lisý Ľ. The new trends in multiple sclerosis treatment. Neurol. praxi. 2020;21(2):120-124. doi: 10.36290/neu.2020.059.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andravizou A, Dartiotis E, Artemiadis A, Sokratous M, Siokas V, Tsouris T, Alouizou AM, Nikolaidis I, Bakirtzis Ch, Tsivgoulis G, Deretzi G, Grigoriadis N, Bogdanos DP, Hadjigeorgiou M. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Autoimmunity Highlights 2019; 10(7): 1-25. Go to original source... Go to PubMed...
    2. Aslami MK, Hamid KM, Naser NH, Mirshafiey A. The Role Autoantibodies in Diagnosis of Multiple Sclerosis. International Trends in Immunity 2014; 2(1): 29-35.
    3. Birnbaum G, Stulc J. High dose biotin treatment for progressive multiple sclerosis. Multiple Sclerosis and Related Disorders 2017; 18: 141-143. Go to original source... Go to PubMed...
    4. Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting cells in relapsing - remittting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017; 10(1): 51-66. Go to original source... Go to PubMed...
    5. Bowen JD. Highly Aggressive Multiple Sclerosis. Continuum ANA 2019; 25(3): 689-714. Go to original source... Go to PubMed...
    6. Cotsapas Ch, Mitrovic M. Genome-wide association studies of multiple sclerosis. Clinical and Translational Immunology 2018; 7: e1018. Go to original source... Go to PubMed...
    7. Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao Ch, Gomwez R, Ragan NR, Rush GQ, Barba PO, Santaniello, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL. Silent progression in immunopathology of multiple sclerosis. Ann Neurol. 2019; 85: 653-666. Go to original source... Go to PubMed...
    8. Eshaghi A, Kievit RA, Prados F, Sudre CH, Nicholas J, Cardoso MJ, Ourselin S, Greenwood J, Thompson AJ, Alexander DC, Barkhof F, Chataway J, Ciccarelli O. Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. PNAS 2019; 116(22): 11020-11027. Go to original source... Go to PubMed...
    9. Favaretto A, Lazarotto A, Margoni M, Poggiali D, Gallo P. Effects of disease modifying therapies on brain and gray mater atrophy in relapsing remitting multiple sclerosis. Multiple sclerosis and demyelinating disorders 2018; 3(1): 1-10 (7). Go to original source...
    10. Fillipi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple sclerosis. Nature Reviews (Disease Primers) 2018; 4: 43. Go to original source... Go to PubMed...
    11. Fox RJ, Coffez ChS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M,Naismith RT, Ashokkumar A, Barnes J. Phase 2 Trial of Ibudilast in Progressivce Multiple Sclerosis N Engl J Med. 2018; 379: 846-855. Go to original source... Go to PubMed...
    12. Freedman MS, Selchen D, Prat A, Giacomini PS. Managing multiple sclerosis: Treatment initiation, modification, and sequencing. Can J Neurol Sci. 2018; 45: 489-503. Go to original source... Go to PubMed...
    13. Ghezzi A. European and American Guidelines for Multiple Sclerosis Treatment. Neurol Ther. 2018; 7: 189-19. Go to original source... Go to PubMed...
    14. Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics 2017; 14: 874-887. Go to original source... Go to PubMed...
    15. Gregson A, Thomson K, Tsirka SE, Selwood DL. Emerging small-molecule treatments for multiple sclerosis: focus on B cells. F1000 Research 2019; 8(245): 1-20. Go to original source... Go to PubMed...
    16. Hu Ye, Garg N, Rammohan KW. Immunopathogenesis of multiple sclerosis. Practical Neurology 2019; 18(2): 61-64.
    17. Isobe N. Genetics in multiple sclerosis: Updates in the era of big data. Clinical and Experimental Neuroimmunology 2018; 10: 1-6. Go to original source...
    18. Killestein J, Oosten B. Emerging safety issues in alemtuzumab-treated MS patients. Multiple sclerosis journal 2019; 25(9): 1206-1208. Go to original source... Go to PubMed...
    19. Koskimäki F, Bernard J, Zong J, Arndt N, Caroll T, Lee SK, Reder AT, Javed A. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLOS one 2018; 13(12): 1-14. Go to original source...
    20. Lassmann H, Brück W, Lucchinetti C. Heterogenicity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends in Molecular Medicine 2001; 7(3): 115-121. Go to original source... Go to PubMed...
    21. Kremer D, Akkermann R, Küry P, Dutta R. Current advancements promoting remyelination in multiple sclerosis. Multiple Sclerosis 2019; 25(1): 7-14. Go to original source... Go to PubMed...
    22. Metz LM. Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis. Continuum AAN 2019; 25(3): 670-688. Go to original source... Go to PubMed...
    23. Mutero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy Ther Adv Neurol Disord. 2018; 11: 1-6. Go to original source... Go to PubMed...
    24. Negron A, Robinson RR, Stüve O, Forsthuber TG. The role of B cells in multiple sclerosis: Current and future therapies. Cellular Immunology 2019; 339: 10-23. Go to original source... Go to PubMed...
    25. Piket E, Zheleznyakova GY, Kular L, Jagodic M. Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview. J of Autoimmunity. 2019; 101: 17-25. Go to original source... Go to PubMed...
    26. Rommer PS, Milo R, Han MH, Satyanaryan S, Sellner J, Hauer J, Illes Z, Warnke C, Laurent S, Weber MS, Zhang Y, Suve O. Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology 2019; 10: 1-25. Go to original source... Go to PubMed...
    27. Ruggieri S, Pontecorvo S, Tortorella C, Gasperini C. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives Multiple Sclerosis and Demyelinating Disorders 2018; 3-5: 1-12. Go to original source...
    28. Sorensen PS, Sellbierg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019; 12: 1-16. Go to original source... Go to PubMed...
    29. Tremblay M. Emerging therapies for progressive multiple sclerosis. Practical Neurology 2019; 18(2): 46-55. Go to PubMed...
    30. Valente LA, Begg LR, Filano AJ. Updating neuroimmune target in central nervous system dysfunction. Trends in Pharmacological Sciences 2019; 4: 1-13. Go to original source... Go to PubMed...
    31. Waslo C, Bourdette D, Gray N, Wright K, Spain R. Lipoic acid and Other Antioxidants as Therapies for Multiple Sclerosis. Curr Treat Options Neurol. 2019; 21: 1-26. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.